

Sanofi
Form 6-K
April 25, 2012

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2012

Commission File Number: 001-31368

SANOFI

(Translation of registrant's name into English)

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

Edgar Filing: Sanofi - Form 6-K

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If Yes marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

In April 2012, Sanofi issued the press release attached hereto as Exhibit 99.1 which is incorporated herein by reference.

Exhibit List

Exhibit	No.	Description
Exhibit 99.1		Press release dated April 24, 2012: Significant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received Lemtrada TM * (Alemtuzumab) Compared With Rebif [®] in Phase III Trial

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: April 25, 2012

SANOFI

By /S/ John Felitti

Name: John Felitti

Title: Associate Vice President, Corporate Law, Financial &
Securities Law

Exhibit Index

Exhibit	No.	Description
Exhibit 99.1		Press release dated 24, 2012: Significant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received Lemtrada™* (Alemtuzumab) Compared With Rebif® in Phase III Trial